The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.
about
Strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia.Dynamics and potential impact of the immune response to chronic myelogenous leukemiaSuboptimal responses in chronic myeloid leukemia: implications and management strategiesPotential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.
P2860
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The achievement of durable com ...... prolonged response at 6 years.
@en
The achievement of durable com ...... prolonged response at 6 years.
@nl
type
label
The achievement of durable com ...... prolonged response at 6 years.
@en
The achievement of durable com ...... prolonged response at 6 years.
@nl
prefLabel
The achievement of durable com ...... prolonged response at 6 years.
@en
The achievement of durable com ...... prolonged response at 6 years.
@nl
P2093
P1476
The achievement of durable com ...... prolonged response at 6 years.
@en
P2093
Anna Franceschino
Enrico M Pogliani
Federica Andreoni
Federica Colnaghi
Gianmarco Corneo
Lucia Tornaghi
Rocco G Piazza
P304
P356
10.1016/J.BCMD.2006.06.002
P577
2006-08-14T00:00:00Z